Cardiac hypertrophy occurs as an adaptation to hypertension but a sustained hypertrophic response can ultimately lead to heart failure. Angiotensin-II (Ang II) is released following hemodynamic overload and stimulates a cardiac hypertrophic response. AngII also increases expression of the regulatory cytokine, transforming growth factor-b1 (TGFb1), which is also implicated in the cardiac hypertrophic response and can stimulate activation of Smad2/3 as well as TGFb-activated kinase 1 (TAK1) signaling mediators. To better understand the downstream signaling events in cardiac hypertrophy, we therefore investigated activation of Smad2/3 and TAK1 signaling pathways in response to Ang II and TGFb1 using primary neonatal rat cardiomyocytes to model cardiac hypertrophic responses. Small interfering RNA (siRNA) knockdown of Smad 2/3 or TAK1 protein or addition of the TGFb type I receptor inhibitor, SB431542, were used to investigate the role of downstream mediators of TGFb signaling in the hypertrophic response. Our data revealed that TGFb1 stimulation leads to cardiomyocyte hypertrophic phenotypes that were indistinguishable from those occurring in response to Ang II. In addition, inhibition of the TGFb1 type receptor abolished Ang II-induced hypertrophic changes. Furthermore, the hypertrophic response was also prevented following siRNA knockdown of TAK1 protein, but was unaffected by knockdown of Smad2/3 proteins. We conclude that Ang II-induced cardiomyocyte hypertrophy in vitro occurs in a TAK1-dependent, but Smad-independent, manner.
INTRODUCTION
Hypertension causes an increased cardiovascular mechanical load that can deleteriously affect heart function. An early myocardial response is an increase in cardiac Angiotensin II (Ang II) protein levels, which is intimately associated with the pathogenesis of cardiac hypertrophy and heart failure. 1, 2 Furthermore, upregulation of Ang II stimulates transforming growth factor-b1 (TGFb1) expression in the myocardium, which also stimulates hypertrophic responses in the heart. 1, [3] [4] [5] Moreover, Ang II-induced cardiac hypertrophy has been shown to be TGFb1-dependent in vivo, revealing the close interaction between Ang II and TGFb-mediated responses in this pathology, 6 although the exact nature of this interaction remains unclear.
To promote TGFb signaling, TGFb1 ligand first binds to the TGFb type II receptor (TGFBR2) at the cell surface stimulating it to activate the TGFb type I receptor (TGFBR1, also known as ALK5), which in turn phosphorylates downstream SMAD2 and SMAD3 proteins. These activated SMAD proteins translocate to the nucleus in complex with SMAD4, where they regulate the transcription of TGFb-target genes. 7 In addition to the canonical SMAD-dependent signaling pathway, TGFb can activate other signaling molecules including TGFb-activated kinase 1 (TAK1, also known as MAP3K7). TAK1 is a central mediator in the inflammatory response. 8 It is also rapidly phosphorylated in cardiomyocytes following exposure to TGFb1, and is activated in the mouse myocardium following pressure overload. 9 Furthermore, overexpressed constitutively active TAK1 leads to cardiac hypertrophy and heart failure in a mouse model, 9 and activated TAK1 is associated with the hypertrophic response in spared cardiomyocytes following myocardial infarction. 10 We have previously shown a direct association between TAK1 and TGFBR2, which may facilitate ligand-dependent activation of TAK1 by ALK5, to stimulate a MAP kinase signaling cascade and cardiomyocyte hypertrophy. 11 As TGFb ligand is involved in activation of both the SMAD2/3 and the TAK1 signaling pathways, we were interested to determine the importance of each of these signaling cascades to the hypertrophic response.
To address this question we used a well-established in vitro model of cardiomyocyte hypertrophy. When cultured rat neonatal cardiomyocytes are treated with hypertrophic agents, such as Endothelin-1 or Ang II, they undergo a series of changes that model aspects of the hypertrophic response, including an increase in cell size, reorganization of contractile proteins and the re-expression of fetal cardiac genes such as brain natriuretic peptide. 2, 12 We have previously shown that endothelin-1 and Ang II generated a very similar hypertrophic response in vitro. 13 Using this model we now show that Ang IIstimulated cardiomyocyte hypertrophy is dependent on TGFb receptor activity and requires the presence of TAK1, but not SMAD2/3.
METHODS

Antibodies and reagents
Primary antibodies were anti-Smad2 (#3122), anti-Smad3 (#9513), anti-phospho Smad2 (#3101) and anti-TAK1 (#4505) from New England Biolabs (Hitchin, UK). Secondary antibody was Goat anti-Rabbit IgG conjugated to horseradish peroxidase (#111-035-144; Jackson ImmunoResearch Laboratories, Newmarket, UK). Ang II (A9525) and SB431542 (S4317) were from Sigma (Poole, UK), and recombinant TGFb1 (100-21R) was from PeproTech EC (London, UK).
Animals
Sprague-Dawley rats were obtained from Charles River Laboratories (Margate, UK). All animal experiments were complied with the United Kingdom Animal Scientific Procedures Act 1986 as well as with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and were approved by the ethical committee of Newcastle University.
Cell culture
Primary cultures of neonatal ventricular cardiomyocytes from 2-day-old Sprague-Dawley rats were prepared as previously described. 13 Heart ventricles were digested with collagenase (0.4 mg ml À1 ) and pancreatin (0.6 mg ml À1 ) in 116 mM NaCl, 20 mM HEPES (pH 7.35), 0.8 mM NaH 2 PO 4 , 5.6 mM glucose, 5.4 mM KCl and 0.8 mM MgSO 4 . The recovered cells were pre-plated for 30 min on 60 mm Primaria culture dishes in plating medium (70% Dulbecco's modified Eagle's medium, 15% M199, 15% fetal calf serum, 100 units per ml penicillin and streptomycin) and non-adherent primary neonatal cardiomyocytes (PNCM) were transferred to gelatin-coated 60-mm Primaria culture dishes for 18 h, before changing to serum-free maintenance media (80% Dulbecco's modified Eagle's medium, 20% M199, 100 units per ml penicillin and streptomycin). Cardiomyocyte purity was routinely 85%, as judged by positive sarcomeric a-actinin staining.
Hypertrophy assays
Cardiomyocytes were stimulated with either 200 nM Ang II or 5 ng ml À1 TGFb1 for 4 h before analysis of changes in gene expression using real-time reversetranscription PCR, and for 48 h before analysis of changes in cytoskeleton and cell morphology. For real-time reverse-transcription PCR, RNA was isolated using RNeasy kits (Qiagen, Crawley, UK) and converted to complementary DNA using a high-capacity reverse transcription kit (Applied Biosystems, Paisley, UK), according to manufacturers' protocols. Expression of the following hypertrophic and endogenous control genes were measured using the TaqMan 7900HT Fast real-time PCR system and assay probe sets (Applied Biosystems) for brain natriuretic peptide (Rn00580641_m1), hypoxanthine guanine phosphoribosyl transferase gene (Rn01527840_m1) and glyceraldehyde-3-phosphate dehydrogenase endogenous control VIC probe (4352338E). Data are presented as mean+s.e.m. of Rq values from three independent experiments. To examine changes in cell morphology and cytoskeleton, cells were fixed in 4% paraformaldehyde, stained with FITC-conjugated Phalloidin (Sigma) for 30 min and mounted in Vectashield with 4' ,6-diamidino-2-phenylindole (Vector Laboratories, Peterborough, UK). Images were acquired using a Zeiss Axioplan II microscope and cell area was measured with Axiovision software (Zeiss, Welwyn Garden City, UK). Where indicated, SB431542 was used to inhibit Alk5 activity in a similar way to previously published protocols. 14, 15 Small interfering RNA PNCM cells were incubated for 18 h with small interfering RNA (siRNA) oligonucleotides, each consisting of a pool of 3-5 target-specific siRNAs, from Santa Cruz (Heidelberg, Germany). These were Smad2 (sc-77325), Smad3 (sc-77326), TAK1 (sc-36606) or non-targeting scrambled control oligonucleotides (sc-37007) and were used at a concentration of 30 nM to transfect cells using the manufacturer's instructions. Smad2 and Smad3 oligonucleotides were combined with a final oligonucleotide concentration of 60 nM in order to simultaneously reduce both proteins. Transfected cells were incubated for 48 h before the addition of hypertrophic agonists.
Immunoblotting
Cardiomyocyte cell pellets were resuspended in 50 ml ice-cold NTT lysis buffer (100 mM NaCl, 50 mM Tris-HCl (pH 8), 1%Triton X-100, 10 mM NaF) in the presence of protease inhibitors (bestatin, leupeptin, pepstatin A, aprotinin, E64; Sigma) and separated using SDS-PAGE. Protein was transferred to Hybond-P PVDF membrane (GE Healthcare, Little Chalfont, UK) and blocked with PBS/ 0.3% Tween-20/5% skimmed milk before incubation with primary antibody. Washed membranes were incubated with horseradish peroxidase-conjugated secondary antibody and proteins were visualized using Super Signal chemiluminescent substrate (Perbio, Cramlington, UK).
Statistical analysis
Cell area data are presented as mean values, and error bars indicate the s.e.m. from 20 to 30 individual cell measurements. Data were analyzed using two tailed Student t-tests. Gene expression data were analyzed using the RQ Manager 1.2 software (Applied Biosystems), and Rq values from a minimum of three independent experiments were analyzed. Statistical significance was accepted at Po0.05.
RESULTS
Ang II and TGFb1 induce similar hypertrophic responses in vitro
Ang II stimulation of rat PNCM in vitro resulted in rearrangement of cortical cytoskeletal actin to form aligned stress fibers (Figure 1a ). This was accompanied by a 2.3-fold increase in average cellular footprint ( Figure 1b) and a twofold increase in brain natriuretic peptide mRNA expression relative to endogenous control genes hypoxanthine guanine phosphoribosyl transferase and glyceraldehyde-3-phosphate dehydrogenase (Figure 1c) . These phenotypes are similar to previously reported cardiomyocyte hypertrophic responses in vitro. 13, [16] [17] [18] TGFb1 alone also stimulated comparable hypertrophic responses to those induced by Ang II treatment (Figures 1a-c) , and in a similar way to a previous report. 19 Functional TGFb1 signaling is essential for the stimulation of cardiomyocyte hypertrophy by Ang II Immunoblot experiments showed that TGFb1 and AngII stimulated phosphorylation of Smad2 in PNCM cells (Figure 2a) , in a similar way to previous reports. 9, 20, 21 Inhibition of TGFb1 signaling with 6 mM SB431542 blocked phospho-Smad2 responses to Ang II and TGFb (Figure 2a) indicating that the Smad 2 phosphorylation response to Ang II requires TGFb receptor activity. Moreover, when PNCMs were treated with SB431542 inhibitor there was no detectable hypertrophic response to Ang II; cell shape, cytoskeletal actin organization and brain natriuretic peptide expression appeared unchanged and were indistinguishable from untreated control cells (Figures 2b-d) . Thus, Ang II induction of hypertrophic responses in vitro is dependent on TGFb1 signaling in a similar way to previously reported in vivo. 6 Canonical TGFb1 signaling through Smad proteins is not essential for cardiomyocyte hypertrophy induced by Ang II TGFb1 signalling involves both canonical signaling through the Smad2/3 pathway and non-canonical signaling through TAK1. A number of studies have pointed to the importance of TAK1 signalling in the hypertrophic response. 9, 10, 22 We therefore wished to investigate whether either Smad2/3 or TAK1 or both were required for hypertrophic responses in cardiomyocytes in culture. SiRNA oligonucleotide transfection was first used to knockdown the expression of Smad2/3, and scrambled oligos were used to control for non-specific effects of transfection. Downregulation of Smad2/3 proteins did not affect the ability of Ang II to stimulate PNCMs to undergo hypertrophic responses (Figures 3a-d) . There was also a comparable hypertrophic response to TGFb1 treatment, irrespective of Smad2/3 knockdown (Figures 3b-d) , indicating that Smad2/3 proteins are not required for the induction of cardiomyocyte hypertrophy by Ang II or TGFb1.
TAK1 is essential for cardiomyocyte hypertrophy induced by Ang II or TGFb1
To evaluate the importance of TAK1 signaling in hypertrophy, TAK1 protein was reduced in cardiomyocytes by siRNA oligonucleotide transfection (Figure 4a ) and hypertrophic phenotypes were assessed as before. Control cells that retained TAK1 expression displayed the classic hypertrophic changes in cell size and actin fiber rearrangement in response to both Ang II and TGFb1 treatments (Figures 4b and c) . However, these responses were abrogated in cells where TAK1 expression had been reduced by siRNA (Figures 4b-d) , indicating that TAK1 is essential for cardiomyocyte hypertrophy induced in vitro by Ang II or TGFb1.
DISCUSSION
We have shown that Ang II requires functional TGFb1 signaling in order to initiate hypertrophic responses in vitro using a neonatal cardiomyocyte model. Moreover, TGFb1 treatment alone induced hypertrophic phenotypes that were indistinguishable from those initiated by Ang II. Inhibiting TGFb1 signaling with SB431542 prevented Ang II-induced hypertrophy, in agreement with in vivo evidence that TGFb1 signaling is involved in the cardiac hypertrophic response. 6 This intimate association between AngII and TGFbeta signalling has also been shown in mouse models of hypertrophic cardiac myopathy where TGFb1 is an essential mediator of hypertrophy and the Ang II type I receptor antagonist losartin prevented the hypertrophic response. 23 An important finding in our study is that neither Ang II nor TGFb1 stimulated hypertrophy in cardiomyocytes in which TAK1 protein was downregulated by siRNA treatment. These data indicate that AngII and TGFb1 promote a hypertrophic response, which is TAK1-dependent and is consistent with in vivo data showing the importance of TAK1 in cardiac hypertrophy. 9, 10, 22 Our data also suggest that the previously reported TGFb1-dependent induction of cardiac hypertrophy by Ang II in vivo would have required TAK1 activity, but not Smad2/3 signalling. 6 We found that reduction of Smad2/3 proteins did not inhibit the hypertrophic response, suggesting cardiac hypertrophy is Smad2/3 independent. In fact, Smad signaling may have a role in protecting against cardiac hypertrophy as cardiac-specific depletion of the common Smad mediator, Smad4, leads to cardiac hypertrophy in a mouse model even in the absence of any external hypertrophic agonist. 24 We also observed that the treatment with the Alk5 inhibitor SB431542 abolished the hypertrophic response. It has also been shown that Alk5 inhibition in vivo ameliorates the hypertrophic response associated with myocardial infarction. 25 In contrast, myocyte-specific loss of Alk5 activity did not affect the cardiac hypertrophic response to aortic constriction, whereas myocyte-specific loss of Tgfbr2 did lead to reduced TAK1 activity and reduced hypertrophy. 22 This indicates the complexity of the functional interation between TAK1 and the TGFb type I and type II receptors. We have previously shown that Alk5 associates with TAK1 in mammalian cardiomyocyte cells, likely through a common interaction with Tgfbr2, 11 but further work is required to better understand the complex interactions between these three proteins during the hypertrophic response.
In conclusion, we show that TAK1 is downstream from, and essential for, hypertrophic signaling initiated by Ang II or TGFb1 in vitro and that hypertrophic responses occur independently of canonical TGFb1 signaling through Smad proteins. Currently, TAK1 is being actively explored as an immunomodulatory drug target for inflammatory disorders 26 and our findings suggest it would also have benefits in protecting the heart from deleterious remodelling in response to hypertension. 
